The wonder drug that wasn't
Related Articles
- Eptacog-α/factor VIII inhibitor bypassing fraction. // Reactions Weekly;8/20/2011, Issue 1365, p19
The article describes the cases of four patients who experienced hypersensitivity and elevated D-dimer levels while receiving sequential combined bypassing therapy with regimens of eptacog-α and factor VIII inhibitor bypassing fraction.
- Tazarotene triumphs most often when used in combo therapies. Nemec, John // Dermatology Times;Jan2001, Vol. 22 Issue 1, p24
Reports the efficiency of utilizing tazarotene in combination therapy for psoriasis and acne medications in Geneva, Switzerland. Use of potent steroid and ultraviolet B phototherapy in combo therapy; Effect of retinoid on psoriasis plaque elevation and scaling; Potential uses of tazarotene.
- ASB seeks comments on Business Combinations Exposure Drafts. // Accountancy Ireland;Oct2005, Vol. 37 Issue 5, p30
Reports that the Accounting Standards Board (ASB) has published FRED 36 "Business Combinations" and FRED 37 & 38 "Intangible Assets" and "Impairment of Assets." Strategy of ASB for convergence with International Financial Reporting Standards; Issues arising from the convergence; Call for...
- Progress and setbacks on the AIDS front. // U.S. News & World Report;6/14/93, Vol. 114 Issue 23, p34
Comments on issues to be discussed at the upcoming AIDS conference in Berlin. Convergent combination therapy; Concorde trial; Vaccines; Conference sites.
- Hidden mutation kills off triple drug HIV therapy. Brown, Phyllida // New Scientist;7/31/93, Vol. 139 Issue 1884, p6
Reports on the discovery of a flaw in medical student Yung-Kang Chow's claims that a combination of drugs could force HIV to `mutate itself to death'. Basis of Chow's claim on convergent combination therapy; Extra undetected mutation in the reverse transcriptase (RT) gene; Results of Sharon...
- Myopathy induced by statin-ezetimibe combination: Evaluation of potential risk factors. Brahmachari, Ballari; Chatterjee, Suparna // Indian Journal of Pharmacology;Sep/Oct2015, Vol. 47 Issue 5, p563
Although both atorvastatin and ezetimibe may cause myopathy, statin-induced myopathy is less likely at low doses, and ezetimibe is only rarely reported to induce myopathy. Also, ezetimibe is not usually known to potentiate statin-induced myopathy. We report a case of myalgia with elevated serum...
- Janumet approved for NHS Scotland. // GP: General Practitioner;6/11/2010, p4
The article reports that diabetes combination therapy called Janumet has been approved for use in Great Britain's National Health Service (NHS) in Scotland.
- Combined Bezafibrate and Medroxyprogesterone Acetate: Potential Novel Therapy for Acute Myeloid Leukaemia. Khanim, Farhat L.; Hayden, Rachel E.; Birtwistle, Jane; Lodi, Alessia; Tiziani, Stefano; Davies, Nicholas J.; Ride, Jon P.; Viant, Mark R.; Gunther, Ulrich L.; Mountford, Joanne C.; Schrewe, Heinrich; Green, Richard M.; Murray, Jim A.; Drayson, Mark T.; Bunce, Chris M. // PLoS ONE;2009, Vol. 4 Issue 12, p1
Background: The majority of acute myeloid leukaemia (AML) patients are over sixty years of age. With current treatment regimens, survival rates amongst these, and also those younger patients who relapse, remain dismal and novel therapies are urgently required. In particular, therapies that have...
- RP vs. radiation: Combining them may be best option. Gebhart, Fred // Urology Times;4/1/2006, Vol. 34 Issue 4, p14
The article reveals that prostatectomy plus radiation therapy may offer the best patient outcomes. It reports on the debate over radical prostatectomy versus radiation therapy for unfavorable-risk prostate cancer. The article discusses radiation therapy advocate Dr. Mack Roach's call for...
